Synergistic effect of Erythrina variegata L. and tamoxifen against the growth of breast cancer cells

Breast cancer is the most common malignancy and the second leading cause of death in women. While tamoxifen (TAM) remains to be a first-line agent for prevention and treatment of estrogenreceptor (ER) positive breast tumors, TAM resistance represents one of the biggest clinical challenges in breast cancer therapy.